Abstract
The case focuses on the antibiotics crisis / antimicrobial resistance, a global health challenge as described by the World Health Organization. It refers to the overuse, or rather the misuse, of antibiotic medications as bad bacteria multiply and take over the good ones. This makes it difficult for current pharmaceutical companies and other medical institutions to develop new drugs and is becoming a serious threat to human life. It can be deemed as a silent pandemic. Currently, the perception is that senior managers at pharmaceutical companies are having a difficult time in finding the best methods to tackle this challenge due to its complex nature. This case follows the decision-making journey of a pharmaceutical company, Evotec, and narrates how the protagonist rises up to the challenges of drug discovery by partnering with other key players (pharmaceuticals, government institutions, education institutions, etc.).
Objective
- Define and evaluate the decision-making process of senior-level managers in relation to managing an innovation process
- Define and evaluate strategies of a company related to partnerships and intellectual property rights
- Discuss the role of open innovation in tackling global challenges such as the antibiotics crisis. Recognize the link between open innovation and the innovation strategy of a company
- Discuss the challenges related to alliance governance and describe effective ways to tackle the issues
- Understand the dynamics of social networks in organizing innovation
Citation Note
Based on field research
Follow the 'handle' link to access the Case Study on RePub.
For EUR staff members: the Teaching Note is available on request, you can contact us at rsm.nl/cdc/contact/
For external users: follow the link to purchase the Case Study and the Teaching Note.
